Messenger RNA delivery of a dual CD25/CD122 affinity-tuned IL-2 variant prolongs exposure and potentiates antitumor T cell immunity
Preclinical results validate a rational design approach to overcome the limitations of IL-2 therapy and support the clinical evaluation of Alb–IL-2var RNA-LNP for solid cancers.